$173 Million is the total value of Knoll Capital Management, LLC's 19 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 5.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | Biohaven Pharmactl Hldg Co L | $62,074,000 | +112.7% | 857,494 | 0.0% | 35.84% | +30.7% | |
| CRBP | Corbus Pharmaceuticals HLDGS | $42,335,000 | +60.1% | 5,045,870 | 0.0% | 24.44% | -1.6% | |
| APLT | Buy | Applied Therapeutics Inc | $22,992,000 | +9.5% | 650,238 | +1.3% | 13.27% | -32.7% |
| ABEO | Abeona Therapeutics Inc | $8,150,000 | +35.7% | 2,859,767 | 0.0% | 4.70% | -16.6% | |
| ORGS | New | Orgenesis, Inc. | $8,003,000 | – | 1,316,364 | +100.0% | 4.62% | – |
| EIGR | Buy | Eiger Biopharmaceuticals Inc | $5,063,000 | +56.7% | 525,238 | +10.5% | 2.92% | -3.7% |
| AVXL | Anavex Life Sciences Corp | $3,621,000 | +58.7% | 724,205 | 0.0% | 2.09% | -2.5% | |
| XCUR | Exicure Inc | $3,067,000 | +62.2% | 1,277,777 | 0.0% | 1.77% | -0.3% | |
| ENTX | Entera Bio Ltd | $3,013,000 | -8.0% | 1,741,363 | 0.0% | 1.74% | -43.4% | |
| ALDX | Aldeyra Therapeutics Inc | $2,374,000 | +68.8% | 569,405 | 0.0% | 1.37% | +3.8% | |
| BX | Sell | Blackstone Group LP | $2,246,000 | -38.4% | 40,000 | -50.0% | 1.30% | -62.1% |
| LUMN | Centurylink Inc | $2,171,000 | +4.3% | 220,000 | 0.0% | 1.25% | -35.9% | |
| SNGX | Soligenix Inc. | $1,584,000 | +19.6% | 787,830 | 0.0% | 0.91% | -26.5% | |
| MTEM | Molecular Templates | $1,540,000 | +1.7% | 113,905 | 0.0% | 0.89% | -37.5% | |
| DOW | Dow Inc | $1,223,000 | +39.5% | 30,000 | 0.0% | 0.71% | -14.3% | |
| CATS | Catasys Inc | $1,097,000 | +67.5% | 43,034 | 0.0% | 0.63% | +2.9% | |
| BTAI | BioXCel Therapeutics Inc | $1,070,000 | +139.4% | 20,000 | 0.0% | 0.62% | +47.1% | |
| CTVA | Corteva Inc | $811,000 | +15.0% | 30,000 | 0.0% | 0.47% | -29.3% | |
| DD | Dupont de Nemours Inc | $785,000 | +53.3% | 15,000 | 0.0% | 0.45% | -5.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.